Lupin has signed a distribution agreement with LG Life Sciences (South Korea) to launch Insulin Glargine, a novel insulin analogue under the brand name Basugine. According to the agreement, Lupin would be responsible for marketing and sales of Basugine in India.
Insulin Glargine is indicated for once – daily subcutaneous administration for the treatment of adult patients with type I diabetes mellitus or in type II diabetes mellitus; patients who need basal insulin (long acting) for controlling hyperglycemia. The primary activity of insulin, including Insulin Glargine, is the regulation of glucose metabolism. Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Shakti Chakraborty, Group President, India Region Formulations, Lupin said, “I believe that our entry into the insulin analogue market with launch of Basugine is a step in the right direction. Lupin’s foray in this segment will help us further strengthen our Diabetes portfolio enabling us to grow deeper into the diabetes segment and will fuel our growth in the years to come.”
EP News Bureau- Mumbai